Merck & Co denies flouting rules as litigation against HPV vaccines clouds Indian trials segment
This article was originally published in Scrip
A public interest litigation (PIL) concerning the cervical cancer vaccines of Merck & Co (Gardasil) and GlaxoSmithKline (Cervarix) has added to a raft of negatives that have cast a shadow on India’s clinical trials segment, already under intense pressure and faced with a sharp deceleration in growth.
You may also be interested in...
Gilead clarifies position on Cipla’s sub-licensing effort for remdesivir, the investigational antiviral in the global spotlight as a potential treatment for COVID-19.
Sun Pharma says that the first quarter of financial 2021 will likely be challenging across the industry with a lull in new prescriptions in India, especially in the acute and semi-chronic segments. But the firm remains upbeat about its lead psoriasis asset Ilumya, which has inched close to the $100m sales mark in its first full year of commercialization.
Physicians may have new expectations from pharma sales reps in India amid COVID-19 and teleconsulting efforts will likely see a significant uptick, at least until the pandemic plateaus, a new survey finds.